• Login
    Browsing All Christie Publications by Title 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • Browsing All Christie Publications by Title
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • Browsing All Christie Publications by Title
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Browsing All Christie Publications by Title

    • 0-9
    • A
    • B
    • C
    • D
    • E
    • F
    • G
    • H
    • I
    • J
    • K
    • L
    • M
    • N
    • O
    • P
    • Q
    • R
    • S
    • T
    • U
    • V
    • W
    • X
    • Y
    • Z

    xmlui.ArtifactBrowser.ConfigurableBrowse.view

    Sort by:

    Order:

    Results:

    Now showing items 1-20 of 9003

    • List view
    • Grid view
    • title
    • issue date
    • submit date
    • ascending
    • descending
    • 5
    • 10
    • 20
    • 40
    • 60
    • 80
    • 100
      • Thumbnail

        019 Chemotherapy-induced cardiotoxicity: could a translational cardiac MRI model help identify patients at risk?

        Cove-Smith, Laura; Schmitt, M; Dive, Caroline; Backen, Alison C; Mescallado, Nerissa; Roberts, R; Mellor, H; Morris, D; Naish, J; Jackson, A; et al. (2017-04-03)
      • Thumbnail

        1 versus 2-cm excision margins for pT2-pT4 primary cutaneous melanoma (MelMarT): a feasibility study.

        Moncrieff, M; Gyorki, D; Saw, R; Spillane, A; Peach, H; Oudit, Deemesh; Geh, J; Dziewulski, P; Wilson, E; Matteucci, P; et al. (2018-05-30)
        There is a lack of consensus regarding optimal surgical excision margins for primary cutaneous melanoma > 1 mm in Breslow thickness (BT). A narrower surgical margin is expected to be associated with lower morbidity, improved quality of life (QoL), and reduced cost. We report the results of a pilot international study (MelMarT) comparing a 1 versus 2-cm surgical margin for patients with primary melanoma > 1 mm in BT.
      • Thumbnail

        10-year results of the International Breast Cancer Intervention Study II (IBIS-II)

        Cuzick, J; Sestak, I; Forbes, JF; Dowsett, M; Cawthorn, S; Mansel, RE; Loibl, S; Bonanni, B; Howell, Anthony; Centre for Cancer Prevention, Queen Mary University of London, London (2020)
      • Thumbnail

        10-Year results of UK childhood cancer and leukaemia group's (CCLG) UK relapsed Wilms tumour (UKWR) trial

        Moroz, V; Hale, J; Pavasovic, V; Hobson, R; Sartori, P; Saunders, Daniel; Powis, M; Vujanic, G; Pritchard-Jones, K; Vaidya, S; et al. (2019)
      • Thumbnail

        11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome.

        Stewart, P M; Walker, B R; Holder, G; O'Halloran, Domhnall J; Shackleton, C H; Department of Medicine, Queen Elizabeth Hospital, Birmingham, United Kingdom. (1995-12)
        A characteristic feature of the ectopic ACTH syndrome is a state of mineralocorticoid excess, although the etiology remains obscure. Some forms of endocrine hypertension, such as licorice ingestion, have been explained by cortisol acting as a mineralocorticoid in the setting of inhibition or deficiency of 11 beta-hydroxysteroid dehydrogenase (11 beta HSD). This enzyme is responsible for the conversion of cortisol (F) to hormonally inactive cortisone, and its activity in vivo can be inferred from the ratio of the urinary excretion of tetrahydrocortisol (THF) and its isomer (5 alpha THF) to tetrahydrocortisone. Twenty-two patients with Cushing's syndrome (11 pituitary dependent, 9 ectopic, and 2 adrenal adenomas) and 13 controls were studied. Compared to controls. Cushing's patients had a significant increase (P < 0.001) in the excretion of all principal metabolites of F, secondary to a 5- to 6-fold increase in the cortisol secretion rate [median, 34.0 (range, 13.3-327) mg/day in Cushing's vs. 6.1 (range, 2.5-10.3) mg/day in controls]. The THF plus 5 alpha THF/tetrahydrocortisone ratio was significantly increased in Cushing's syndrome regardless of etiology [mean, 1.81 (range, 1.09-9.99) in Cushing's vs. 0.81 (range, 0.51-1.47) in controls; P < 0.001), indicative of defective 11 beta HSD activity. Furthermore, compared to patients with pituitary-dependent Cushing's, this ratio was significantly higher in patients with the ectopic ACTH syndrome (4.12 vs. 1.49; P < 0.01) and was inversely correlated with serum potassium levels (r = -0.57; P = 0.01; n = 22). One explanation for the mineralocorticoid excess state of the ectopic ACTH syndrome appears to be that cortisol gains inappropriate access to the mineralocorticoid receptor through failure of its normal metabolism by 11 beta HSD. The reason for the defective 11 beta HSD activity is unclear, but it may be secondary to substrate saturation, inhibition by other adrenal steroids, or product inhibition.
      • Thumbnail

        11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group.

        Thatcher, Nick; Barber, Philip V; Hunter, Robin D; Carroll, K B; Jegarajah, S; Wilkinson, Peter M; Crowther, Derek (1982-05-08)
        55 patients with inoperable but "limited"-stage small-cell carcinoma were treated sequentially with methotrexate, radiotherapy, and high doses of cyclophosphamide. The treatment was completed over 11 weeks and no maintenance chemotherapy was given. Follow-up lasted 9-29 months. Toxicity was acceptable, despite doses of cyclophosphamide of 1.5-3.5 g/m2. The complete response rate was 53%. Median survival for the total patient group was 12 months, range 2-29+. Patients who attained a complete response had a 17 month median survival; 17 patients remained in complete remission, 9 of whom first underwent treatment 14-29 months previously. Karnofsky performance scores improved after treatment and most patients were able to resume normal activity. The results are similar to those obtained with prolonged combination chemotherapy.
      • Thumbnail

        111: How good is lung cancer education in primary care and how can the Christie Lung Cancer Group improve this?

        Coote, Joanna H; Harris, Maggie A; Summers, Yvonne J; Neocleous, M; Hill, T; Dhamrait, B; Clinical Oncology, The Christie NHS Foundation Trust, Manchester (2017-01)
      • Thumbnail

        1133P Non-elective admissions in cancer care - a review of acute oncology services (AOS) implementation in a north-west region of England.

        Chow, Shien; Leach, Rebecca; Mitchell, Claire L; Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK (2017-09)
      • Thumbnail

        114Inm oxine-labelled lymphocytes--therapeutic applications.

        Hamilton, D; Cowan, Richard A; Drayson, M; Sharma, H; Cummins, P; Nuttall, Pamela M; Deakin, David P; Wagstaff, John; Crowther, Derek; Regional Department of Medical Physics and Bioengineering, Christie Hospital and Holt Radium Institute, Manchester, UK. (1988-10)
        It has shown that, after intravenous administration of autologous lymphocytes labelled with the beta-emitting radionuclide 114Inm, the cells initially migrate normally before succumbing to the toxic effects of the radiation. The radioactive material is then released from the cell and taken up by neighbouring radioresistant macrophages, thereby localizing a field of radiation to the site of lymphocyte death. Using this technique, lymphocytopoenia has been produced in rats. We have measured the whole-body distribution and excretion of radioactivity in patients who received escalating activities of 114Inm-labelled lymphocytes. All patients had active non-Hodgkin's lymphoma involving the spleen and liver which proved resistant to combination chemotherapy and conventional radiotherapy. Following intravenous administration, the labelled cells cleared rapidly from the vasculature with only 15% remaining in the peripheral blood at 30 min. The radioactivity continued to fall over the next 5 days to approximately 3% and was maintained at approximately 2% for up to 90 days. There was an almost immediate uptake of radioactivity by the spleen and liver which reached approximately 85% of the injected dose by 48 h. The localization of radioactivity stabilized by 48 h and thereafter the whole-body content fell by approximately 0.8% per day. Up to 5% of the administered radioactivity accumulated in the bone marrow. The activities administered were too low to produce a therapeutic response and no toxicity was experienced by the patients. A therapeutic study at higher activities is now underway.
      • Thumbnail

        117: Organ at risk inter- and intra-observer contour variation for lung patients on average versus motion compensated 4DCT.

        McWilliam, Alan; Lee, Lip W; Harris, Maggie A; Sheikh, Hamid Y; Pemberton, Laura S; Faivre-Finn, Corinne; van Herk, Marcel; University of Manchester, Division of Molecular and Clinical Cancer Science, Faculty of Biology, Medicine and Health, Manchester (2017-01)
      • Thumbnail

        118: Accelerated hypofractionated intensity modulated radiotherapy (IMRT) for early stage non-small cell lung cancer (NSCLC) in patients not suitable for conventional stereotactic ablative radiotherapy (SABR).

        Lavin, Victoria; Whitehurst, Philip; Harris, Catherine; Goldstraw, Rhiannon; Bayman, Neil A; Chan, Clara; Coote, J.; Harris, Maggie A; Pemberton, Laura S; Sheikh, Hamid Y; et al. (2017-01)
      • Thumbnail

        118 Multiparametric Cardiovascular Magnetic Resonance Surveillance of Acute Cardiac Allograft Rejection and Characterisation of Transplantation-associated Myocardial Injury.

        Miller, C; Naish, J; Shaw, S; Yonan, N; Williams, S; Clark, D; Bishop, P; Ainslie, M; Borg, A; Coutts, Glyn; et al. (2014-06)
        Acute cardiac allograft rejection (ACAR) affects approximately 20% of patients in the first year post-transplantation, represents a leading cause of death during this period and confers higher mortality in patients surviving beyond the first year. Clinical features of ACAR are unreliable, therefore serial surveillance endomyocardial biopsies are performed in order to detect ACAR at an early stage. However the procedure is invasive, is associated with uncommon but significant complications and expensive, factors which prevent more frequent monitoring thus limiting optimal immunosuppression titration. This study aimed to prospectively and longitudinally evaluate the performance of multiparametric cardiovascular magnetic resonance (CMR) for detecting and monitoring ACAR in the early phase post-transplant, and characterise graft recovery following transplantation.
      • Thumbnail

        120: Impact of introducing intensity modulated radiotherapy (IMRT) on curative-intent radiotherapy for lung cancer – a ‘big data’ analysis.

        Chan, Clara; Woolf, David K; Kennedy, Jason; Whitehurst, Philip; Harris, Catherine; Goldstraw, R.; Bayman, Neil A; Coote, J.; Harris, Maggie A; Pemberton, Laura S; et al. (2017-01)
      • Thumbnail

        1259TiP A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i).

        Gasal, E; Arance Fernandez, A; Ascierto, P; Atkinson, V; Dummer, R; Flaherty, K; Grob, J; Hansson, J; Hassel, J; Larkin, J; et al. (2017-09)
      • Thumbnail

        126: Automated classification of radiation oesophagitis from free text clinical narratives.

        Dehghan, Azad; Ala-Aldeen, K; Blaum, C; Liptrot, Tom; Kennedy, Jason; Tibble, Daniel; Barker-Hewitt, Matthew; Faivre-Finn, Corinne; Data Science, Informatics, The Christie NHS Foundation Trust, Manchester (2017-01)
      • Thumbnail

        1303PD Nivolumab in previously treated patients with metastatic squamous NSCLC: results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged >= 70 years and with poor performance status.

        Popat, S; Ardizzoni, A; Ciuleanu, T; Dols, M; Laktionov, K; Szilasi, M; Califano, Raffaele; Costa, E; Griffiths, R; Paz-Ares, L; et al. (2017)
      • Thumbnail

        130: Routine implementation of electronic patient reported outcomes (ePRO) in lung cancer patients.

        Ala'Aldeen, K; Stones, Nicola; Woolf, David K; Bayman, Neil A; Coote, Joanna H; Harris, Maggie A; Pemberton, Laura S; Sheikh, Hamid Y; Chan, Clara; Faivre-Finn, Corinne; et al. (2017-01)
      • Thumbnail

        1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).

        Paz-Ares, L; Socinski, M; Shahidi, J; Hozak, R; Soldatenkova, V; Thatcher, Nick; Hirsch, F; Department of Medical Oncology, University Hospital 12 De Octubre, Madrid, SpainHematology/Oncology, University of Pittsburgh, Pittsburgh, PA (2016-04)
      • Thumbnail

        1345P Intracranial efficacy of brigatinib (BRG) in patients (Pts) with crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases.

        Ou, S-H; Tiseo, M; Camidge, R; Ahn, M; Huber, R; Hochmair, M; Kim, S-W; West, H; Reckamp, K; Molina, J; et al. (2017-09)
      • Thumbnail

        1348P Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: results from two phase II studies.

        Lidbrink, E; Erfan, J; Chmielowska, E; Otremba, B; Bouhlel, A; Lauer, S; Hermoso, M; Nuesch, E; Shing, M; Misra, Vivek; et al. (2017)
        DSpace software (copyright © 2002 - 2022)  DuraSpace
        Quick Guide | Contact Us
        Open Repository is a service operated by 
        Atmire NV
         

        Export search results

        The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

        By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

        To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

        After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.